Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Mark Bishton, Pier Luigi Zinzani, MD PhD, Scott Marshall, Veronica Conteh, Alicia Rodríguez Fernández, SooKyoung Kim, Young Nam Lee

Blood (2019) 134 (Supplement_1): 4135.

https://doi.org/10.1182/blood-2019-121957

Published: 2019

Journal Articles

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma

Miguel A Canales, MD PhD, Thomas A Buchholz, MD, James R Mason, MD, Joana M Parreira, MD, Monique S Tomiczek, MSc, Kai Hübel, MD

Blood (2019) 134 (Supplement_1): 5269.

https://doi.org/10.1182/blood-2019-123638

Published: 2019

Journal Articles

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

My L Nguyen, PharmD, Catherine Burdalski, PharmD, BCOP, Syed Abbas Ali, MD, Lindsay Kohler, BS, PharmD Candidate, Steven Gilmore, PharmD, BCOP

Blood (2019) 134 (Supplement_1): 5811.

https://doi.org/10.1182/blood-2019-125391

Published: 2019

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 2395.

https://doi.org/10.1182/blood-2019-123654

Published: 2019

Journal Articles

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Blood (2019) 134 (Supplement_1): 763.

https://doi.org/10.1182/blood-2019-129097

Published: 2019

Journal Articles

A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds

Blood (2018) 132 (Supplement 1): 487.

https://doi.org/10.1182/blood-2018-99-115495

Published: 2018

Journal Articles

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

Maro N. Ohanian, DO, Tara L Lin, MD, Ellen K. Ritchie, MD, Michael Craig, MD, Apurv Agrawal, MD, Kathleen G. Halka, MD, Vinit Karur, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Sarah Aminov, Miranda Lim, BSN, Sherry A. Pierce, BSN, BA, Natalie Sacarakis, Stacy Minor, Ana Tari Ashizawa, PhD, William Hahne, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2018-99-113693

Published: 2018

Journal Articles

Retrospective Observational Study from the Experience in Our Center of the Employment of Daratumumab in Multiple Myeloma

Estefanía Morente Constantin, Pablo Romero Garcia, Maria Almudena Garcia-Ruiz, Rafael Rios, MD PhD, Esther Clavero Sanchez, Manuel Jurado, MD PhD

Blood (2018) 132 (Supplement 1): 5630.

https://doi.org/10.1182/blood-2018-99-114740

Published: 2018

Journal Articles

Safety of Split First Dosing Vs Standard Dosing Administration of Daratumumab Among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study

Robert M Rifkin, MD, David Singer, PharmD, Kathleen M. Aguilar, MPH, Bismark Baidoo, PhD, Eric M Maiese, PhD

Blood (2018) 132 (Supplement 1): 4846.

https://doi.org/10.1182/blood-2018-99-116808

Published: 2018

Journal Articles

Intrabone Delivery of CD34+ Cells Using an Optimized Delivery System Does Not Enhance Engraftment in a Rhesus Macaque Model of Hematopoietic Stem Cell Transplantation

Blood (2018) 132 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2018-99-114730

Published: 2018

Journal Articles

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Issam S. Hamadeh, PharmD, Justin Arnall, Pharm.D., Ekaterina Kachur, PharmD, Allison Martin, PharmD, Megan Helena Jagosky, MD, Reed Friend, MD, Shebli Atrash, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2018-99-118737

Published: 2018

Journal Articles

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Blood (2017) 130 (Supplement 1): 4321.

https://doi.org/10.1182/blood.V130.Suppl_1.4321.4321

Published: 2017

Journal Articles

Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis

Elena Santagostino, Maria Elisa Mancuso, MD PhD, Cristina Novembrino, Massimo Anzoletti Boscolo, Marigrazia Clerici, Gianluigi Pasta, MD, Luigi Piero Solimeno, MD, Flora Peyvandi

Blood (2017) 130 (Supplement 1): 2360.

https://doi.org/10.1182/blood.V130.Suppl_1.2360.2360

Published: 2017

Journal Articles

Rationale for and Design of a Tolerability and Safety Study of FEIBA Reconstituted in Regular or 50% Reduced Volume and Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors

Talaha Mubarak Ali, Naghmana Bajwa

Blood (2017) 130 (Supplement 1): 4886.

https://doi.org/10.1182/blood.V130.Suppl_1.4886.4886

Published: 2017

Journal Articles

Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

Hallie Barr, PharmD, Jessica Dempsey, PharmD, BCOP, Allyson Waller, PharmD, Ying Huang, MD, Nita Williams, BS, Nidhi Sharma, PhD, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 1889.

https://doi.org/10.1182/blood.V130.Suppl_1.1889.1889

Published: 2017

Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo

Blood (2017) 130 (Supplement 1): 434.

https://doi.org/10.1182/blood.V130.Suppl_1.434.434

Published: 2017

Journal Articles

Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience

Raakhee Shah, MPharm, Simon Cheesman, BPharm, Kirit M Ardeshna, MD, Kate Cwynarski, MD, David C. Linch, FRCP, Andres E. Virchis, FRCP, FRCPath, Jonathan Richard Lambert, Christopher Mcnamara, William Townsend

Blood (2017) 130 (Supplement 1): 3387.

https://doi.org/10.1182/blood.V130.Suppl_1.3387.3387

Published: 2017

Journal Articles

Nonclinical Assessment of Bax 604 (FEIBA STAR) - Reduced Volume Reconstitution & Higher Infusion Rate

Gerald Hoebarth, Alexandra Kopic, Martin Wolfsegger, Cstat (RSS), Alexander Bauer, Peter L. Turecek, PhD, Peter Leidenmuehler, Karima Benamara, Werner Hoellriegl, Marietta Turecek

Blood (2016) 128 (22): 2590.

https://doi.org/10.1182/blood.V128.22.2590.2590

Published: 2016

Journal Articles

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

Soo-Mee Bang, Yeung-Chul Mun, Ho-Jin Shin, MD PhD, Chul Won Jung, Sung Hwa Bae, Sang Kyun Sohn, Kyoung Ha Kim, Hawk Kim, Ho-Young Yhim, MD PhD, Junshik Hong, Hye Joo Kim, Jae-hoon Lee, Doyeun Oh

Blood (2016) 128 (22): 4938.

https://doi.org/10.1182/blood.V128.22.4938.4938

Published: 2016

NARROW

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

Retrospective Observational Study from the Experience in Our Center of the Employment of Daratumumab in Multiple Myeloma

Safety of Split First Dosing Vs Standard Dosing Administration of Daratumumab Among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study

Intrabone Delivery of CD34+ Cells Using an Optimized Delivery System Does Not Enhance Engraftment in a Rhesus Macaque Model of Hematopoietic Stem Cell Transplantation

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis

Rationale for and Design of a Tolerability and Safety Study of FEIBA Reconstituted in Regular or 50% Reduced Volume and Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors

Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience

Nonclinical Assessment of Bax 604 (FEIBA STAR) - Reduced Volume Reconstitution & Higher Infusion Rate

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only